- Novel method for preparing repaglinide intermediate
-
The invention discloses a novel process for preparing a repaglinide intermediate, which takes o-fluorobenzonitrile as an initial raw material and obtains a target product that is repaglinide racematethrough a Grignard reaction, a condensation reaction and a reduction reaction. The novel synthetic process is high in yield, suitable for industrial mass production, economical and environment-friendly, and the target product can be further used for preparing the medicine repaglinide for treating diabetes mellitus through condensation.
- -
-
Paragraph 0036; 0037
(2020/11/01)
-
- Preparation of 3-methyl-1 - [2 - (1-piperidinyl) phenyl] ding Yaan and the method of use of the product of
-
The invention discloses a method for preparing 3-methyl-1-(2-(1-piperidyl) phenyl) butyl imine and the application of the 3-methyl-1-(2-(1-piperidyl) phenyl) butyl imine. The yield of the 3-methyl-1-(2-(1-piperidyl) phenyl) butyl imine is 30 to 35 percent; the purity of the 3-methyl-1-(2-(1-piperidyl) phenyl) butyl imine is 99.0 to 99.5 percent (detected by an HPLC (high performance liquid chromatography) method); the 3-methyl-1-(2-(1-piperidyl) phenyl) butyl imine can be used as a standard substance for detecting impurities during the preparation of repaglinide amine, and can also be used for preparing high-purity repaglinide amine after subjected to catalytic hydrogenation or preparing 3-methyl-1-(2-(1-piperidyl) butanone after subjected to acidolysis; and the prepared 3-methyl-1-(2-(1-piperidyl) butanone can be used as raw material for synthesizing repaglinide amine or 3-methyl-1-(2-(1-piperidyl) phenyl) butyl imine, so as to be recycled, and raw material waste is avoided. The method is applicable to the synthesis of repaglinide amine.
- -
-
-
- Process for the preparation of substantially optically pure Repaglinide and precursors thereof
-
The invention relates to a process for preparing substantially optically pure Repaglinide and pharmaceutically acceptable salts, solvates and esters thereof, as well as precursors therefore.
- -
-
Page/Page column 14
(2010/05/13)
-
- An improved process for repaglinide via an efficient and one pot process of (1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butan-1-amine - A useful intermediate
-
The development of a large-scale synthesis for (1S)-3-methyl-1-(2- piperidin-1-ylphenyl)butan-1-amine (S-(+)-1), a key intermediate of repaglinide (2), is described. The process conditions for S-(+)-1 involving nucleophilic substitution, Grignard reaction, reduction and resolution were optimized and telescoped. The racemization of the undesired enantiomer R-(-)-1 offers a distinctive advantage in terms of cost and overall yield over the existing process. This communication also describes the control of a DCU byproduct obtained during the condensation of S-(+)-1 with phenyl acetic acid derivative 3 in the synthesis of 2. Schweizerische Chemische Gesellschaft.
- Kolla, Naveenkumar,Elati, Chandrashekar R.,Vankawala, Pravinchandra J.,Gangula, Srinivas,Sajja, Eswaraiah,Anjaneyulu, Yerremilli,Bhattacharya, Apurba,Sundaram, Venkataraman,Mathad, Vijayavitthal T.
-
p. 593 - 597
(2007/10/03)
-
- Repaglinide and related hypoglycemic benzoic acid derivatives
-
The structure-activity relationships in two series of hypoglycemic benzoic acid derivatives (5, 6) were investigated. Series 5 resulted from meglitinide (3) when the 2-methoxy was replaced by an alkyleneimino residue. Maximum activity was observed with the cis-3,5-dimethylpiperidino (5h) and the octamethyleneimino (5l) residues. Series 6 resulted from the meglitinide analogon 4 bearing an inversed amido function when the 2-methoxy, the 5- fluoro, and the α-methyl residue were replaced by a 2-piperidino, a 5- hydrogen, and a larger α-alkyl residue, respectively. An alkoxy residue ortho to the carboxy group further increased activity and duration of action in the rat. The most active racemic compound, 6al (R4 = isobutyl; R = ethoxy), turned out to be 12 times more active than the sulfonylurea (SU) glibenclamide (1). Activity was found to reside predominantly in the (S)- enantiomers. Compared with the SUs 1 and 2 (glimepiride), the most active enantiomer, (S)-6al (AG-EE 623 ZW; repaglinide; ED50 = 10 μg/kg po), is 25 and 18 times more active. Repaglinide turned out to be a useful therapeutic for type 2 diabetic patients; approval was granted recently by the FDA and the EMEA. From investigations on the pharmacophoric groups in compounds of type 5 and 6, it was concluded that in addition to the two already known - the acidic group (COOH; S02NH) and the amidic spacer (CONH; NHCO) - the ortho residue R1 (alkyleneimino; alkoxy; oxo) must be regarded as a third one. A general pharmacophore model suitable for hypoglycemic benzoic acid derivatives, SUs, and sulfonamides is proposed (Figure 6). Furthermore, from superpositions of low-energy conformations (LECs) of 1, 2, and (S)-6al, it was concluded that a common binding conformation (LEC II; Figure 10B) may exist and that differences in binding to the SU receptor and in the mechanism of insulin release between repaglinide and the two SUs may be due to specific hydrophobic differences.
- Grell, Wolfgang,Hurnaus, Rudolf
-
p. 5219 - 5246
(2007/10/03)
-